A Phase III Extension Study of Udenafil in Adolescents With Single Ventricle Physiology After Fontan Palliation

Trial Profile

A Phase III Extension Study of Udenafil in Adolescents With Single Ventricle Physiology After Fontan Palliation

Recruiting
Phase of Trial: Phase III

Latest Information Update: 30 Aug 2017

At a glance

  • Drugs Udenafil (Primary)
  • Indications Congenital heart defects; Ventricular dysfunction
  • Focus Adverse reactions
  • Sponsors Mezzion
  • Most Recent Events

    • 20 Apr 2017 Status changed from not yet recruiting to recruiting.
    • 29 Mar 2016 New trial record
    • 23 Mar 2016 According to a Mezzion Pharma media release, the US FDA recently completed a special protocol assessment (SPA) review of two Phase III clinical protocols directed to the use of udenafil in adolescents with single ventricle congenital heart disease with Fontan physiology. Udenafil was granted Orphan Drug designation by the FDA in 2015.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top